Article
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy…
Prostate Cancer · 2022 · Rahul Aggarwal, author Joshi J. Alumkal, author Russell Z. Szmulewitz, author Celestia S. Higano, author Alan H. Bryce, author Angela Lopez-Gitlitz, author Sharon A. McCarthy, author Branko Miladinovic, author Kelly McQuarrie, author Shibu Thomas, author Ke Zhang, author Eric J. Small, author Shikha Goyal, Academic Editor
Key facts
| Title | Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer |
|---|---|
| First author | Rahul Aggarwal, author Joshi J. Alumkal, author Russell Z. Szmulewitz, author Celestia S. Higano, author Alan H. Bryce, author Angela Lopez-Gitlitz, author Sharon A. McCarthy, author Branko Miladinovic, author Kelly McQuarrie, author Shibu Thomas, author Ke Zhang, author Eric J. Small, author Shikha Goyal, Academic Editor |
| Journal | Prostate Cancer |
| Published | Apr 25, 2022 |
| DOI | 10.1155/2022/5454727 |
| Product codes mentioned | GAD |
At a glance
- None FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1